

बिड दस्तावेज़ / Bid Document

बिड विवरण/Bid Details

| | |
|---|---|
| बिड बंद होने की तारीख/समय /Bid End Date/Time | 01-04-2026 12:00:00 |
| बिड खुलने की तारीख/समय /Bid Opening Date/Time | 01-04-2026 12:30:00 |
| बिड पेशकश वैधता (बंद होने की तारीख से)/Bid Offer Validity (From End Date) | 90 (Days) |
| मंत्रालय/राज्य का नाम/Ministry/State Name | Chandigarh |
| विभाग का नाम/Department Name | Education Department Chandigarh |
| संगठन का नाम/Organisation Name | Government Medical College And Hospital |
| कार्यालय का नाम/Office Name | Sector 32, Chandigarh |
| कुल मात्रा/Total Quantity | 7200 |
| वस्तु श्रेणी /Item Category | Heparin Injection (Q2) |
| बिडर का न्यूनतम औसत वार्षिक टर्नओवर (3 वर्षों का) /Minimum Average Annual Turnover of the bidder (For 3 Years) | 3 Lakh (s) |
| मूल उपकरण निर्माता का औसत टर्नओवर (गत 3 वर्षों का)/OEM Average Turnover (Last 3 Years) | 15 Lakh (s) |
| टर्नओवर के लिए एमएसई को छूट प्राप्त है / MSE Relaxation for Turnover | Yes Complete |
| टर्नओवर के लिए स्टार्टअप को छूट प्राप्त है / Startup Relaxation for Turnover | Yes Complete |
| विक्रेता से मांगे गए दस्तावेज़/Document required from seller | Bidder Turnover,Certificate (Requested Turnover *In case any bidder is seeking exemption supporting documents to prove his eligibility evaluation by the buyer |
| क्या आप निविदाकारों द्वारा अपलोड किए गए दस्तावेज़ों को निविदा में भाग लेने वाले सभी निविदाकारों को दिखाना चाहते हैं? संदर्भ मेनू है/Do you want to show documents uploaded by bidders to all bidders participated in bid? | Yes (Documents submitted as part of a tender/bid process will also be displayed) |
| बिड लगाने की समय सीमा स्वतः नहीं बढ़ाने के लिए आवश्यक बिड की संख्या। / Minimum number of bids required to disable automatic bid extension | 3 |
| दिनों की संख्या, जिनके लिए बिड लगाने की समय-सीमा बढ़ाई जाएगी। / Number of days for which Bid would be auto-extended | 7 |
| ऑटो एक्सटेंशन अधिकतम कितनी बार किया जाना है। / Number of Auto Extension count | 1 |
| बिड से रिवर्स नीलामी सक्रिय किया/Bid to RA enabled | Yes |

बिड विवरण/Bid Details

| | |
|--|--|
| रिवर्स नीलामी योग्यता नियम/RA Qualification Rule | H1-Highest Priced Bid Elimination |
| बिड का प्रकार/Type of Bid | Two Packet Bid |
| तकनीकी मूल्यांकन के दौरान तकनीकी स्पष्टीकरण हेतु अनुमत समय /Time allowed for Technical Clarifications during technical evaluation | 5 Days |
| निरीक्षण आवश्यक (सूचीबद्ध निरीक्षण प्राधिकरण /जेम के साथ पूर्व पंजीकृत एजेंसियों द्वारा)/Inspection Required (By Empanelled Inspection Authority / Agencies pre-registered with GeM) | No |
| मूल्यांकन पद्धति/Evaluation Method | Total value wise evaluation |
| मध्यस्थता खंड/Arbitration Clause | Yes (Arbitration clause document) as per Arbitration should not be routinely inclu |
| सुलह खंड/Mediation Clause | No |

ईएमडी विवरण/EMD Detail

| | |
|-----------------------------|---------------------|
| एडवाइजरी बैंक/Advisory Bank | State Bank of India |
| ईएमडी राशि/EMD Amount | 11838 |

ईपीबीजी विवरण /ePBG Detail

| | |
|---|---------------------|
| एडवाइजरी बैंक/Advisory Bank | State Bank of India |
| ईपीबीजी प्रतिशत (%) /ePBG Percentage(%) | 5.00 |
| ईपीबीजी की आवश्यक अवधि (माह) /Duration of ePBG required (Months). | 12 |

(a). जेम की शर्तों के अनुसार ईएमडी छूट के इच्छुक बिडर को संबंधित केटेगरी के लिए बिड के साथ वैध समर्थित दस्तावेज प्रस्तुत करने है। एमएसई केटेगरी के लिए सेवा प्रदाता ईएमडी से छूट के पात्र हैं। व्यापारियों को इस नीति के दायरे से बाहर रखा गया है।/EMD EXEMPTION: The bidder seeking EMD document for the relevant category as per GeM GTC with the bid. Under MSE category, only manufacturers for good: exemption from EMD. Traders are excluded from the purview of this Policy.

(b).ईएमडी और संपादन जमानत राशि, जहां यह लागू होती है, लाभार्थी के पक्ष में होनी चाहिए। / EMD & Performance security should be in f

लाभार्थी /Beneficiary :

Director Principal
Government Medical College and Hospital, Sector 32, Chandigarh
(Prof Ravneet Kaur Bedi)

बोली विभाजन लागू नहीं किया गया/ Bid splitting not applied.

एमआईआई खरीद वरीयता / MII Purchase Preference

| | |
|--|-----|
| एमआईआई खरीद वरीयता / MII Purchase Preference | Yes |
|--|-----|

Traders are excluded from the purview of Public Procurement Policy for Micro and Small Enterprises. In respect of bid provider of the offered Service. Relevant documentary evidence in this regard shall be uploaded along with the bid if not an MSE and MSE Seller (s) has/have quoted price within L-1+ 15% of margin of purchase preference /price band given opportunity to match L-1 price and contract will be awarded for 25 % percentage of total quantity. The buyers dated 18.05.2023. [OM No.1 4 2021 PPD dated 18.05.2023](#) for compliance of Concurrent application of Public Procurement Order, 2012 and Public Procurement (Preference to Make in India) Order, 2017.

7. Estimated Bid Value indicated above is being declared solely for the purpose of guidance on EMD amount and for Over, Past Performance and Project / Past Experience etc. This has no relevance or bearing on the price to be quoted impact on bid participation. Also this is not going to be used as a criteria in determining reasonableness of quoted price based on its own assessment of reasonableness and based on competitive prices received in Bid / RA process.

8. Reverse Auction would be conducted amongst all the technically qualified bidders except the Highest quoting bidder will not be allowed to participate in RA. However, H-1 will also be allowed to participate in RA in following cases:

- If number of technically qualified bidders are only 2 or 3.
- If Buyer has chosen to split the bid amongst N sellers, and H1 bid is coming within N.
- In case Primary product of only one OEM is left in contention for participation in RA on elimination of H-1.
- If L-1 is non-MSE and H-1 is eligible MSE and H-1 price is coming within price band of 15% of Non-MSE L-1
- If L-1 is non-MII and H-1 is eligible MII and H-1 price is coming within price band of 20% of Non-MII L-1

Heparin Injection (7200 pieces)

(क्रमशः श्रेणी 1 और श्रेणी 2 के स्थानीय आपूर्तिकर्ता के रूप में अर्हता प्राप्त करने के लिए आवश्यक/Minimum 50% and 20% Local Content 2 Local Supplier respectively)

तकनीकी विशिष्टियाँ /Technical Specifications

* जेम केटेगरी विशिष्टि के अनुसार / As per GeM Category Specification

| विवरण/Specification | विशिष्टि का नाम /Specification Name | बिड के लिए आवश्यक अनुमत |
|--------------------------|--|-------------------------|
| PRODUCT INFORMATION | Medicine Name | Heparin |
| | Dosage Form | Injection |
| | Strength | 5000 IU/mL |
| | Compliance to uploaded Special Terms and Conditions | Yes |
| PACKAGING | Type of primary packing | Vial |
| | Primary pack size | 5 ml |
| CERTIFICATIONS & REPORTS | Availability of valid drug manufacturing license issued from the competent authority defined under Drugs and Cosmetic Act and Rules there under as amended till date | Yes |
| | Submission of all necessary certifications, licenses and test reports to the buyer as per buyer requirement at the time of bid submission and along with supplies | Yes |

परेषिती/रिपोर्टिंग अधिकारी तथा मात्रा/Consignees/Reporting Officer and Quantity

| क्र.सं./S.No. | प्रेषिती/रिपोर्टिंग अधिकारी /Consignee Reporting/Officer | पता/Address | डिलीवरी अनुसू तारीख से दिनों |
|---------------|--|--|------------------------------------|
| 1 | Kuldeep Kaur | 160031, Government Medical College & Hospital Sector 32, Chandigarh, 160031 | मात्र /Quantity 3600 3600 |

Special terms and conditions-Version:1 effective from 14-11-2025 for category Heparin Injection

1. The sellers are registered on GeM and exempted from the Vendor Assessment process based on the Manufacturing Drug License certified by the issuing authority. Buyers must mandatorily ask for submit regulatory documents applicable with the bid. Buyers must also check and validate the details e.g., val drug/medicine under procurement, the license issuing authority etc. at their end.
2. The Buyer shall ask the seller to submit the "Notarized Undertaking" in the mentioned below format (sc may be verified by the buyer at their end.

UNDERTAKING

(to be on non-judicial stamp paper of Rs 10 and not)

I, _____, s/o / d/o / w/o _____, aged about _____ resident of _____ undertake that;

1. I am the partner / proprietor / director of _____ (name of entity) and duly _____ (Name of entity)
2. We are the manufacturers of the drug/medicine _____ ("Product") and intend to offer
3. We state that the license for the Product has been granted/obtained by us as per the provisions there under as amended till date.
4. We further state that the details regarding the Product/licenses have been uploaded by us on the of the Drugs and Cosmetics Rules, 1945 as amended till date. Reference no. for SUGAM portal is _____
5. We undertake that all the information provided above is true and complete in all respect. We un information/declaration is provided by us, suitable legal action/action as per Drugs and Cosmetic there under will be initiated.

Place:

Date:

.....

Signature, Name, Designation & Seal

on behalf of the Manufacturer

3. All Provisions of Drugs and Cosmetics Act, 1940 and Rules made there under as amended till date will a notifications issued by *Central Drugs Standard Control Organization (CDSCO)*, Ministry of Health & Fam Pharmaceuticals (DOP), Ministry of Chemicals & Fertilizers time to time in this regard.
4. All provisions of Narcotic Drugs & Psychotropic Substances Act, 1985 as amended till date will also be a Substances.
5. The purchase shall be made through Bidding/RA only irrespective of the value.
6. Manufacturer shall have a valid own manufacturing license issued by the competent drug licensing autl 1940 and Rules made there under as amended till date. The Drug/medicine quoted should be clearly m License. The valid own manufacturing license shall be submitted to the buyer at the time of bid submis

In case of authorized resellers/distributors, it will be the legal & regulatory liability of the manufacturer are operating in compliance with all relevant laws and regulations and are properly licensed to sell the

Manufacturer shall be responsible for verifying the validity and authenticity of drug license held by the

If revalidation of drug license has been applied for, the buyer shall be informed accordingly and the copy must be submitted with a certificate that application for renewal was made within time frame as per DR that has not been deleted by drug licensing authority.

7. Bidder/Seller shall submit the valid GMP/WHO-GMP Certificate of the manufacturing site as per revised by the Concerned Drug Licensing Authority to the buyer at the time of bid submission.
8. Bidder/Seller shall submit a valid **non-Conviction** certificate for last two (2) consecutive years issued to the buyer at the time of bid submission. The certificate must have been issued within 12 months from the date of bid submission.
9. Bidder/Seller shall submit **Manufacturing & Market Standing certificate** (in India) issued by the concerned authority for last 2 consecutive years for the drug/medicine quoted to the buyer at the time of bid submission. The drug/medicine name shall be highlighted.

This would not apply to drugs, which were introduced in India less than 2 years ago. A certificate from the concerned authority for all new drug formulations to this effect.

10. If a company/firm has two or more separate manufacturing units at different sites / States/region, which shall be allowed to submit only one bid for all units but necessary document regarding separate manufacturing units shall be submitted. Only one bidder will be allowed to submit only one offer for one product.
11. The manufacturer shall have in house testing facilities and valid Good Laboratory Practice (GLP) Certificate issued by the concerned authority under the Act and Rules made thereunder as amended up to date issued by Central / State Drug Controller / FDA.
12. Bidder/Seller shall have Maximum Production Capacity Certificate (section wise) issued by concerned drug controller for the product.
13. STP (Standard Testing Procedure) along with the required reference standards for non-Pharmacopoeia shall be submitted by the bidder/seller at the time of submission of the bid.
14. The bidder/seller shall submit complete stability data (long term stability studies and accelerated stability studies) for at least 3 batches whenever required by the buyer. For New drugs/medicines, complete stability data shall be submitted (If manufacturer has licensed a formula from another company and such licensed formula is used for the product, the license should be submitted along with licensing agreement.)
15. The bidder/seller should have not been blacklisted/debarred/de-registered/banned for the quoted product by any Central or State Government's Drug procurement agencies at the time of submission of bid. Further, the bidder/seller should not have been blacklisted / debarred / de-registered/banned due to quality failure, such bidder/seller or their Partner should not participate in the bid.
16. During the validity of the bid if the firm/Company is blacklisted/debarred/de-registered/banned by any Central or State Government's Drug procurement agencies / convicted by any Court of law in India, it shall be intimated to the buyer by the bidder/seller firm/ company within one month.
17. During Contract period, if the supplier is debarred/deregistered /blacklisted/ banned by any Central Government's Drug procurement agencies due to quality failure, buyer may cancel the contract and go for fresh bid as per discretion of the buyer.
18. The firm/company/ corporation and any of its director/proprietors/ partners/ Authorized signatories should not be blacklisted or pending in any court of India by any department of Govt. under prevention of Corruption Act or for corruption in the Government fund or any criminal conspiracy in the said matter at the time of submission of bid.
19. Bidder/seller should submit a notarized undertaking on an affidavit of Rs. 100/- (Rupees One Hundred only) in the following format.

They will comply with all the statutes & legislation regarding manufacturing, import, sale, and supply of drugs/medicines as per the Acts/Enactments viz., The Drugs and Cosmetics Act, 1940, The Drugs and Cosmetics Rules, 1945 (as amended up to date), The Drugs (Control) Act, 1950, The Indian Statistical Institute Act, 1959, GST Act.

To supply drugs of standard quality as prescribed under the provisions of Drug and Cosmetic Act, 1940 and to supply items/drugs "not of standard", "Grossly sub-standard" and "Spurious and adulterated drugs" as per the order of the Controller of India from time to time.

20. The price offered by the seller/bidder shall not, in any case, exceed the DPCO/NPPA controlled price or ceiling price. If the seller must reduce the prices if there is any reduction in DPCO/NPPA ceiling price or price fixed by State Government.
21. Guidelines of Department of Pharmaceuticals applicable as nodal ministry for implementing the provisions of the Drugs and Cosmetics (India) order (PPO) 2017-revision as amended to date, related to procurement of Goods & Services in Pharmacy.
22. **Fall Clause:** Provision of fall clause will not be applicable on the sale of drugs which have an expiry date of more than 31026/1/2019-Policy dated 12-9-2020.
23. **Shelf Life:** Shelf life of each quoted drugs/medicines shall be in accordance with Schedule P of Drugs and Cosmetics Act, 1940.

In case pre-dispatch inspection is not applicable, the life of the drugs/medicines shall not have passed the shelf life of the drug/medicine at the time of delivery to the consignee.

In case of pre-dispatch inspection, at the time when the stores are offered for inspection, the life of the one sixth (1/6th) of the total shelf life of the drugs/medicines.

24. **Recalls**

If products are recalled because of problems with product quality or adverse reaction to the pharmacist/buyer, providing full details about the reason leading to the recall, and shall take steps to replace the product at its ultimate destination with a fresh batch of acceptable pharmaceuticals or withdraw and give a full refund if the product has been taken off the market due to safety problems.

25. **Inspection, Testing and Quality Control**

- All the batches of the drugs/medicines supplied shall be accompanied with in-house **Test Report** from the supplier's own Quality Control Lab. The Test Report/Certificate of Analysis shall include:
 1. Generic name of the product
 2. Batch No.
 3. Pharmacopoeia Reference and/ or In-house method
 4. Batch quantity
 5. Date of manufacture
 6. Expiry date
 7. Date of test
 8. Description (clarity, color etc)
 9. All identity, potency, purity, sterility, pyrogen and all other test required by the specified pharmacopoeia. Results and the limits for the individual tests should be given
 10. Conclusion
 11. Qualified Person's signature

The above-mentioned batch shall be manufactured in accordance with the applicable GMP regulations.

- Buyer will embark on stringent quality checks to ensure that drugs/medicines/goods meet requirements. Buyer reserves the right to carry necessary inspections/tests from NABL Accredited/Government approved laboratory. A combination of or/ all following stages:

a) At Pre-Dispatch stage

b) At Delivery Stage: Inspection done once the drugs/medicines/goods reach at consignee location inventory.

c) Post Delivery Surveillance: The Drugs/Medicines/goods shall have the active ingredients as indicated in official compendiums or technical specifications throughout the shelf-life period of the drug. The surveillance may also be organized by the buyer post-delivery.

- The Buyer may engage the services of a Quality Control Agent & Quality Control Testing Laboratory. The sampling quantities shall be borne by the supplier.
- The buyer's right to inspect, test and, where necessary reject the drugs/medicines/goods after their destination shall in no way be limited or waived by reason of the goods having previously been in transit to the destination from the place of manufacture.
- **Inspection Methodology:** At pre-dispatch and/or delivery stage, samples of supplies in each batch shall be collected and sent to designated laboratories (NABL Accredited/Government approved laboratories).

At post-delivery surveillance - The samples will be collected from the warehouse of buyer/or designated Quality Control Labs in respect of supplied drugs/medicines/goods at any point during the shelf life.

Handling and testing charges will be borne by the buyer for the above purpose.

- In case of failure of batches during or at any stage (indicated above), the testing charges would be borne by the supplier.
- The supplies will be deemed to be completed only upon receipt of the quality certificates from the supplier. If the supplies are found to be "Not of Standard Quality" or spurious or adulterated or misbranded, such batch/ batches will be rejected. The cost of entire batch paid will be recovered from the supplier when the batch is found to be "Not of Standard Quality" or spurious or adulterated or misbranded.
- **At any of testing stage,** Samples which do not meet quality requirement shall render the relevant batch declared to be "Not of Standard Quality" or spurious or adulterated or misbranded, such batch/batches of drugs/medicines/goods and the cost of entire batch paid will be recovered from the supplier when the batch is found to be "Not of Standard Quality" or spurious or adulterated or misbranded.
- If any inspected or tested drugs/medicines/goods fails to conform to the specifications or fails in any of the tests, the supplier will be responsible to take back the rejected drugs/medicines/goods from the depots/consignees and supply fresh stock duly inspected and tested within 45 days from the date of intimation from the buyer. The buyer has the right to destroy such rejected drugs/medicines/goods if the supplier does not take back the rejected drugs/medicines/goods within stipulated time. The buyer will arrange to destroy the "NOT OF STANDARD QUALITY ITEMS" after the expiry of the stipulated time.

Action may also be initiated by the buyer for debarring/blacklisting against the supplier for suitable concerned State will also be informed by the buyer for initiating necessary action on the supplier be forfeited without any intimation.

The decision of the buyer or any officer authorized by buyer, as to the quality of the supplied drug

- In case any drug/medicine is found substandard either any of testing stage or during the shelf life approved laboratory shall be accepted by the supplier/seller. If the same is disputed by the supplier sent to Central Drug Laboratory, Kolkata, and the report of CDL will only be accepted as final and submitted within three months, from the date of communication of the disputed test report to the approach the concerned Drug Control Authorities for getting the drugs/medicines tested, as per own cost.

The de-registration / debarment action will be taken by the buyer against the manufacturing unit category-A and category-B defects as per guidelines issued by the Ministry of Health & Family Welfare communicated to GeM.

- The supplier shall furnish evidence of the basis for shelf life and other stability data concerning the buyer. In case of any complaint in the field, the B.M.R/ B.P.R for the particular batch of the product For New drugs/medicines, complete stability data of 6 months period shall be acceptable.
- The case of admixture of drugs will be treated as a violation of terms and conditions and will not
- Statutory provisions on manufacture, distribution, storage and quality issues of drugs/medicines up to date is vested with the DCGI (CDSCO)/ MoH& FW, including its Central/ Zonal/ Regional Drug confiscation, sealing or prosecution with relation to drugs/medicines under the said Act is also with
- In accordance with the provisions of Sec 22 & 31 of the Drugs and Cosmetic Act, 1940, as amended Controller/ Drug Inspector may exercise their powers as an Inspecting Agency.

26. **Deduction, Blacklisting, and other penalties on account of Quality failure**

The suitable conditions may be added by the buyer in the bid through Additional Term & Conditions (ATC)

27. **Quality Test by Statutory Authorities:**

If any batch of any product(s) supplied by the supplier is declared "NOT OF STANDARD QUALITY", by any authority, the supplier shall inform the same immediately to the buyer so that the use of the available stock of the available stock of the product with all consignee/users will be retrieved.

28. **Termination for Default**

The buyer may without prejudice to any other remedy for breach of contract, by written notice of default whole or in part If the supplier fails to promptly replace any drug/medicine/goods rejected submitted for applicable Regulatory Authority in the country of manufacture due to unacceptable quality or reports of the recall.

29. **Warranty**

- Supplies must fully comply in all respect with the Technical specifications and conditions laid down Pharmacopoeia standards.
- Each supply should be accompanied with a "Warranty Certificate" duly signed by the Bidder as under

"The Supplier/Seller hereby declares that the stores as detailed below sold to the buyer under the workmanship and shall be strictly in accordance with the specifications and particulars mentioned the stores would continue to conform to the description of and quality aforesaid for a period of specified shelf life from the date of delivery of the said stores to the buyer, have overages within and are not subject to recall by the applicable Regulatory Authority due to unacceptable quality. Notwithstanding the above, the fact that the said stores fail to conform to the description and quality decision of the buyer in that behalf is final and conclusive, the buyer will be entitled to reject the discovered not to conform to the said description and quality. Losses due to premature deterioration potency will be made good and supplied by the firm at its own cost at consignee's site.

On such rejection, the stores will be at the seller's risk and all provisions herein contained relating to supplier/Seller shall if so called upon to do so by the buyer in writing, replace the stores free of cost within forty five days or such further period as may be extended from time to time by the buyer at his cost. The supplier/seller after the stores or such portion of the stores thereof as is rejected by the buyer a period shall apply to the stores replaced from the date of the replacement thereof otherwise the as may arise by reason of the breach of the conditions. Nothing herein contained shall prejudice this contract or otherwise".

| Sl. No. & Date | Nomenclature & Specification | Name & Address of Manufacturing Unit | Batch No. | DOM & DOE |
|----------------|------------------------------|--------------------------------------|-----------|-----------|
|----------------|------------------------------|--------------------------------------|-----------|-----------|

Signature name & designation

- If the supplier, having been notified, fails to replace within the period specified above, the buyer may be necessary/deemed fit by the buyer, at the suppliers' risk and expense and without prejudice against the supplier under the contract.

30. **Packaging, Labelling and Marking Requirements**

Packaging, Labelling and Marking shall be as per the provisions contained in the Drugs and Cosmetics Act/ Rules, 1930 as amended up-to-date, other particulars of packaging, labelling & marking, if any, prescribed by the buyer. Additional Terms and Conditions (ATC) shall be complied with.

31. **Bar Coding**

All drugs/medicines supplied should incorporate GS1 barcodes standards at various packaging levels (primary, secondary and tertiary) and should encode the information within the barcodes as mentioned by the buyers in addition to other requirements. Details of bar-coding will be given by the buyer through Additional Terms and Conditions (ATC).

32. **Delivery Period**

- Minimum delivery period will be of 45 days from the date of issuing of the purchase order.
 - The supplier should maintain the recommended temperature of the drug/medicine (wherever indicated) and if found that temperature has not been maintained, supply against the said order is liable to be rejected.
 - The items requiring special cold storage conditions shall be supplied with cold chain transporting unit to the warehouses/consignee location.
33. Any specific requirements for the packaging, labelling, logograms, printing, artwork, bar coding or any other requirements shall be mentioned in Additional Terms and Conditions (ATC) in the bid will be applicable.
34. Any other Terms and Conditions which is not included or at variance with the conditions specified in Standard Terms and Conditions (STC) and Additional Terms and Conditions (ATC) in the bid to ensure drugs/medicines are procured from authentic quality. The above terms and conditions are in reverse order of precedence i.e., ATC shall supersede STC and STC shall supersede General Terms and Conditions (GTC), whenever there are any conflicting provisions.

क्रेता द्वारा जोड़ी गई बिड की विशेष शर्तें/Buyer Added Bid Specific Terms and Conditions

1. **Buyer Added Bid Specific ATC**

Buyer Added text based ATC clauses

| Sr no | Certificate/documents required from the firm for purchase of Inj. Heparin 25000IU vial (IV, SC) |
|-------|---|
| 1 | Complete specification with packing detail need to be mentioned by supplier (including label of offered product). |
| 2 | Valid manufacturing License from principal manufacturing firm to manufacture the product issued by State licensing authority should be submitted. |
| 3 | Valid Certificate of Good Manufacturing Practice (GMP) under Schedule M/ revised Schedule M of Drug & Cosmetic Act/ WHO GMP and if license is issued by state Food licensing authority then ISO certificate/Quality Management system (QMS) and if license issued under Medical Devices 2017, then no requirement of QMS/GMP/ISO from Principal Manufacturer. |

| | |
|----|--|
| 4 | If bid is submitted by the distributor/ sister concern/ authorized dealer on the behalf of the Principal manufacturing firm, then the authority letter (bid specific) should be submitted along with the tender. |
| 5 | Certificate from the firm that the rates quoted by them are Hospital rate and not higher than those quoted with other Government, public sector and private organizations. |
| 6 | L1 firm required to get advance sample approved from buyer before commencement of supply |
| 7 | Stamping- "GMCH -32, Chandigarh supply not for sale" stamping is required and test reports with each supply/batch, a test report of the same batch/ supply should be provided from approved laboratory of Drug Controller. |
| 8 | Solvency certificate issued from the bank |
| 9 | L1 firm may be asked to sign Integrity Pact in due course of time |
| 10 | Affidavit as per annexure-I from Principal manufacturing Firm |
| 11 | Turnover of 03 financial year (out of last 04 financial years) is required to be submitted from firm |

ANNEXURE- I

AFFIDAVIT

(Note:- To be furnished (original) on non judicial stamp paper duly attested by the Notary).

(to be required from principal manufacturer)

I/We(Name) _____ partner/sole proprietor of (Firm)_____ firm to the fact that

- 1) The individual firm/companies are neither black listed nor convicted by the Union or Centre or State Government directly connected with or has any subsisting interest in business of my/our firm.
- 2) Will comply with all the statutes & legislation regarding manufacturing, import, sale, and supply of drugs in terms viz., The Drugs and Cosmetics Act, 1940, The Drugs and Cosmetics Rules, 1945 (as amended), The Legal I, The Indian Statistical Institute Act, 1959, GST Act.

"To supply drugs of standard quality as prescribed under the provisions of Drug and Cosmetic Act, 1940 (as a s "not of standard", "Grossly sub-standard" and "Spurious and adulterated drugs" as per the latest guidelines o time"

Date

DEPONENT

Place

Address:

I/we do hereby solemnly declare and affirms that the above declaration true and correct to the best of my knowledge and nothing has been concealed.

Date: _____

DEPONENT

Place

अस्वीकरण/Disclaimer

The additional terms and conditions have been incorporated by the Buyer after approval of the Competent Authority. The organization is solely responsible for the impact of these clauses on the bidding process, its outcome, and consequences arising in the bidding process due to these ATCs and due to modification of technical specifications and / or terms and conditions are incorporated by the Buyer regarding following, the bid and resultant contracts shall be treated as null and void at any stage of bidding process without any notice:-

1. Definition of Class I and Class II suppliers in the bid not in line with the extant Order / Office Memorandum issued.
2. Seeking EMD submission from bidder(s), including via Additional Terms & Conditions, in contravention to extant policy.
3. Publishing Custom / BOQ bids for items for which regular GeM categories are available without any Category based ATC.
4. Creating BoQ bid for single item.
5. Mentioning specific Brand or Make or Model or Manufacturer or Dealer name.
6. Mandating submission of documents in physical form as a pre-requisite to qualify bidders.
7. Floating / creation of work contracts as Custom Bids in Services.
8. Seeking sample with bid or approval of samples during bid evaluation process. (However, in bids for [attached](#) procurement policy of the buyer nodal Ministries)
9. Mandating foreign / international certifications even in case of existence of Indian Standards without specifying.
10. Seeking experience from specific organization / department / institute only or from foreign / export experience.
11. Creating bid for items from irrelevant categories.
12. Incorporating any clause against the MSME policy and Preference to Make in India Policy.
13. Reference of conditions published on any external site or reference to external documents/clauses.
14. Asking for any Tender fee / Bid Participation fee / Auction fee in case of Bids / Forward Auction, as the case may be.
15. Buyer added ATC Clauses which are in contravention of clauses defined by buyer in system generated bid terms and conditions, EMD Detail, ePBG Detail and MII and MSE Purchase Preference sections of the bid, unless otherwise allowed by the system.
16. In a category based bid, adding additional items, through buyer added additional scope of work/ additional terms and conditions, needs more items along with the main item, the same must be added through bunching category based item BoQ with the main category based item, the same must not be done through ATC or Scope of Work.

Further, if any seller has any objection/grievance against these additional clauses or otherwise on any aspect of this same by using the Representation window provided in the bid details field in Seller dashboard after logging in as a seller, he is duty bound to reply to all such representations and would not be allowed to open bids if he fails to reply to such representations.

All GeM Sellers/Service Providers shall ensure full compliance with all applicable labour laws, including guidelines under the four Labour Codes i.e. the Code on Wages, 2019; the Industrial Relations Code, 2020; the Code on Social Security, 2020; and the Code on Occupational Safety, Health and Compensation for Injury, 2020 as and when notified and brought into force.

For all provisions of the Labour Codes that are pending operationalisation through rules, schemes or notifications, the pre-existing labour enactments (such as The Minimum Wages Act, 1948, The Payment of Wages Act, 1947, The Equal Remuneration Act, 1976, The Payment of Gratuity Act, 1972, etc. and relevant State Rules) shall continue to apply until the new provisions are operationalised.

The Seller/ Service Providers shall, therefore, be responsible for ensuring compliance under:

- All notified and enforceable provisions of the new Labour Codes as mentioned hereinabove; and
- All operative provisions of the erstwhile Labour Laws until their complete substitution.

All obligations relating to wages, social security, safety, working conditions, industrial relations etc. are strictly met by the Seller/ Service Provider. Any non-compliance shall constitute a breach of the contract and appropriate action in accordance with the contract and applicable law.

[यह बिड सामान्य शर्तों के अंतर्गत भी शासित है /This Bid is also governed by the General Terms and Conditions](#)

जेम की सामान्य शर्तों के खंड 26 के संदर्भ में भारत के साथ भूमि सीमा साझा करने वाले देश के बिडर से खरीद पर प्रतिबंध के संबंध में भाग लेने के लिए तभी पात्र होगा जब वह बिड देने वाला सक्षम प्राधिकारी के पास पंजीकृत हो। बिड में भाग लेते समय बिडर को अपने देश के कानून का अनुपालन न करने पर अनुबंध को तत्काल समाप्त करने और कानून के अनुसार आगे की कानूनी कार्रवाई का आधार होगा।/In terms of a country which shares a land border with India, any bidder from a country which shares a land border with India will be eligible to bid in this tender only if the bidder is registered with the competent authority. Bidding in this tender will be subject to the bidder's compliance with the laws of the country of origin. Any false declaration and non-compliance of this would be a ground for immediate termination of the contract and further legal action in accordance with the applicable law.

---धन्यवाद/Thank You---